Healthcare / Medical DevicesNYSE
$34.47
-0.18 (-0.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $150.9M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
19.5x
↓EV/EBITDA
10.6x
↓ROE
4.6%
↑Gross Margin
54.6%
↑Debt/Equity
0.81
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+4.4%
FCF CAGR
+26.3%
FCF margin
11.0%
FCF / Net income
3.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.37B · net income $47.1M · FCF $150.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $1.37B | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B | $862.5M | $955.1M | $859.6M | $796.4M | $763.5M | $719.2M | $740.1M | $762.7M | $767.1M | $725.1M | $713.7M | $694.7M |
| Net Income | $47.1M | $47.1M | $132.4M | $64.5M | $-80.6M | $62.5M | $9.5M | $28.6M | $40.9M | $55.5M | $14.7M | $30.5M | $32.2M | $35.9M | $40.5M | $752000.00 | $30.3M | $12.1M |
| EBITDA | $176.5M | $176.5M | $272.2M | $192.5M | $27.6M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 1.51 | 1.51 | 4.25 | 2.04 | -2.68 | 1.94 | 0.32 | 0.97 | 1.41 | 1.97 | 0.52 | 1.09 | 1.16 | 1.28 | 1.41 | 0.03 | 1.05 | 0.42 |
| Gross Margin | 54.6% | 54.6% | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% | 54.9% | 54.6% | 54.1% | 53.5% | 53.1% | 54.6% | 54.1% | 52.9% | 51.7% | 51.2% | 48.6% |
| Operating Margin | 7.5% | 7.5% | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% | 8.3% | 8.3% | 5.9% | 4.9% | 7.1% | 7.1% | 7.4% | 8.5% | 1.1% | 8.0% | 4.1% |
| Net Margin | 3.4% | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% | 3.0% | 4.8% | 7.0% | 1.9% | 4.2% | 4.3% | 4.7% | 5.3% | 0.1% | 4.3% | 1.7% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.81 | 0.81 | 0.94 | 1.17 | 1.41 | — | — | — | 0.66 | 0.75 | 0.84 | 0.46 | 0.41 | 0.35 | 0.26 | 0.16 | 0.15 | — |
| Current Ratio | 2.29 | 2.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $150.9M | $150.9M | $153.9M | $106.3M | $11.6M | $96.9M | $51.5M | $75.1M | $58.2M | $52.7M | $25.1M | $35.9M | $49.8M | $62.5M | $73.7M | $85.4M | $23.5M | $3.6M |
| Returns | ||||||||||||||||||
| ROE | 4.6% | 4.6% | 13.8% | 7.7% | -10.8% | 8.0% | 1.3% | 4.0% | 6.2% | 8.8% | 2.5% | 5.2% | 5.5% | 5.9% | 6.7% | 0.1% | 5.2% | 2.1% |
| Valuation | ||||||||||||||||||
| P/E | 19.47 | 19.47 | 15.99 | 52.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 10.58 | 10.58 | 11.01 | 22.45 | 139.04 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.04 | 1.04 | 2.20 | 4.04 | 3.76 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 5.2% | 5.2% | 5.0% | 19.1% | — | 17.2% | -9.7% | 11.1% | 7.9% | 4.3% | 6.2% | -2.8% | -3.0% | -0.6% | 5.8% | 1.6% | 2.7% | — |
| EPS Growth | -64.5% | -64.5% | 108.3% | 176.1% | — | 506.2% | -67.0% | -31.2% | -28.4% | 278.8% | -52.3% | -6.0% | -9.4% | -9.2% | 4600.0% | -97.1% | 150.0% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
26.5%
EPS terminal req.
$3.06
Spread vs growth
-91.0%
5Y implied EPS CAGR
19.6%
EPS terminal req.
$3.70
Spread vs growth
-84.1%
10Y implied EPS CAGR
14.7%
EPS terminal req.
$5.96
Spread vs growth
-79.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.4%
Start / end P/E
13.0x → 22.8x
EPS bridge
4.25 → 1.51
Residual
-48.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.